1. Home
  2. KC vs SUPN Comparison

KC vs SUPN Comparison

Compare KC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kingsoft Cloud Holdings Limited

KC

Kingsoft Cloud Holdings Limited

SELL

Current Price

$8.44

Market Cap

2.7B

Sector

Technology

ML Signal

SELL

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

SELL

Current Price

$37.86

Market Cap

2.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KC
SUPN
Founded
2012
2005
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.5B
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
KC
SUPN
Price
$8.44
$37.86
Analyst Decision
Strong Buy
Buy
Analyst Count
14
4
Target Price
$20.20
★ $60.50
AVG Volume (30 Days)
★ 1.2M
627.8K
Earning Date
11-18-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $392,755,000.00
Revenue This Year
$32.74
$22.95
Revenue Next Year
$27.68
$54.39
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.35
$39.36
52 Week High
$18.52
$59.68

Technical Indicators

Market Signals
Indicator
KC
SUPN
Relative Strength Index (RSI) 35.18 27.30
Support Level $8.35 N/A
Resistance Level $9.46 $52.33
Average True Range (ATR) 0.29 1.58
MACD -0.02 -0.38
Stochastic Oscillator 8.84 6.09

Price Performance

Historical Comparison
KC
SUPN

About KC Kingsoft Cloud Holdings Limited

Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: